<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325271</url>
  </required_header>
  <id_info>
    <org_study_id>VEGF Bio</org_study_id>
    <nct_id>NCT02325271</nct_id>
  </id_info>
  <brief_title>Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers</brief_title>
  <official_title>Intra-individual Variability and Circadian Rhythm of Systemic Vascular Endothelial Growth Factor (VEGF) Levels and Interaction With Biomarkers of Inflammation in Subjects With Normal Glucose Tolerance (NGT) and Patients With Type 2 Diabetes Without Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the intra-individual variability of VEGF levels over a period of 6 months
      as well as the circadian variation of VEGF levels, both under standardized conditions in
      patients with type 2 diabetes without DME and matched subjects with normal glucose tolerance
      (NGT). Secondary objectives of the study are to evaluate the relationship of individual
      VEGF-levels to biomarkers of inflammation, HbA1c and major cardiovascular risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VEGF-A</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Plasma levels determined in the morning under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-B</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Plasma levels determined in the morning under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-C</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Plasma levels determined in the morning under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placental growth factor</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Plasma levels determined in the morning under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-A</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Plasma levels determined over the day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-B</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Plasma levels determined over the day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-C</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Plasma levels determined over the day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placental growth factor</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Plasma levels determined over the day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Plasma levels determined in the morning under fasted conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein (hCRP)</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Serum levels determined in the morning under fasted conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrix metallopeptidase 9 (MMP-9)</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Plasma levels determined in the morning under fasted conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMP-9</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Plasma levels determined over the day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Serum levels determined in the morning under fasted condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Serum levels determined over the day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Serum levels determined in the morning under fasted condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>Hourly over 12 hours</time_frame>
    <description>Serum levels determined over the day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Urine levels determined in the morning under fasted condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Urine levels determined in the morning under fasted condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Serum levels determined in the morning under fasted condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline, month 1, 2, 3, 4, 5 and 6, once over 24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Subjects with normal glucose tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes group</arm_group_label>
    <description>Patients with type 2 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Frequent blood and urine sampling and blood pressure measurement</intervention_name>
    <description>Blood and urine sampling for the determination of VEGF and biomarkers</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Diabetes group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample of healthy volunteers, type 2 diabetes patients of the study center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age equal to or between 50 and 80 years

          -  Subjects with normal glucose tolerance confirmed by glucose tolerance test (control
             group) or patients with type 2 diabetes: diabetes duration 5-25 years; HbA1c equal to
             or between 6.5 and 9% (diabetes group)

          -  Ability to understand and follow study-related instructions

        Exclusion Criteria:

          -  DME

          -  hsCRP &gt; 10 mg/dl

          -  Acute infections

          -  Acute or chronic inflammatory diseases

          -  Immune diseases

          -  Treatment with immune suppressive drugs

          -  Treatment with glucocorticoids

          -  Myocardial infarction and stroke within 1 year before inclusion

          -  Hemorrhage within the previous 5 years

          -  Surgeries within the previous 3 months

          -  Oncological diseases

          -  Women who are pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markolf Hanefeld, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study center Prof. Hanefeld, GWT-TUD GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GWT-TUD GmbH / Studienzentrum Hanefeld</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

